These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 22041253

  • 41. A randomized double-blind study of the effect of Botox and Dysport/Reloxin on forehead wrinkles and electromyographic activity.
    Karsai S, Adrian R, Hammes S, Thimm J, Raulin C.
    Arch Dermatol; 2007 Nov; 143(11):1447-9. PubMed ID: 18025375
    [No Abstract] [Full Text] [Related]

  • 42. Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy.
    Hexsel D, Brum C, Porto MD, Soirefmann M, Siega C, Schilling-Souza J, Rodrigues TC.
    J Drugs Dermatol; 2013 Dec; 12(12):1356-62. PubMed ID: 24301236
    [Abstract] [Full Text] [Related]

  • 43. A Prospective, Split-Face, Randomized, Double-Blind Study Comparing OnabotulinumtoxinA to IncobotulinumtoxinA for Upper Face Wrinkles.
    Yeilding RH, Fezza JP.
    Plast Reconstr Surg; 2015 May; 135(5):1328-1335. PubMed ID: 25919246
    [Abstract] [Full Text] [Related]

  • 44. The severity of wrinkling at the forehead is related to the degree of ptosis of the upper eyelid.
    Ezure T, Amano S.
    Skin Res Technol; 2010 May; 16(2):202-9. PubMed ID: 20456101
    [Abstract] [Full Text] [Related]

  • 45. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
    Hanke CW, Narins RS, Brandt F, Cohen JL, Donofrio LM, Downie J, Heinz M, Harrington L, McDaniel DH, Nestor M, Schlessinger J, Schlöbe A, Taub A, Weiss RA.
    Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
    [Abstract] [Full Text] [Related]

  • 46. Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives.
    Lowe NJ.
    Dermatol Surg; 1998 Nov; 24(11):1216-8. PubMed ID: 9834741
    [Abstract] [Full Text] [Related]

  • 47. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids.
    Carruthers A, Carruthers J.
    Dermatol Surg; 2005 Oct; 31(10):1297-303. PubMed ID: 16188182
    [Abstract] [Full Text] [Related]

  • 48. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study.
    Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH.
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):171-8. PubMed ID: 23301821
    [Abstract] [Full Text] [Related]

  • 49. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
    Moers-Carpi M, Dirschka T, Feller-Heppt G, Hilton S, Hoffmann K, Philipp-Dormston WG, Rütter A, Tan K, Chapman MA, Fulford-Smith A.
    J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
    [Abstract] [Full Text] [Related]

  • 50. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides.
    Matarasso SL.
    Dermatol Surg; 2003 Jan; 29(1):7-13; discussion 13. PubMed ID: 12534505
    [Abstract] [Full Text] [Related]

  • 51. Eyebrow height after botulinum toxin type A to the glabella.
    Carruthers A, Carruthers J.
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S26-31. PubMed ID: 17241411
    [Abstract] [Full Text] [Related]

  • 52. Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?
    Carruthers A, Carruthers J, Cohen J.
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S97-104. PubMed ID: 17241422
    [Abstract] [Full Text] [Related]

  • 53. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis.
    Talarico-Filho S, Mendonça DO Nascimento M, Sperandeo DE Macedo F, DE Sanctis Pecora C.
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S44-50. PubMed ID: 17241414
    [Abstract] [Full Text] [Related]

  • 54. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA.
    Yu KC, Nettar KD, Bapna S, Boscardin WJ, Maas CS.
    Arch Facial Plast Surg; 2012 Jan; 14(3):198-204. PubMed ID: 22183059
    [Abstract] [Full Text] [Related]

  • 55. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
    Ozer IS, Kuzu Kumcu M, Tezcan Aydemir S, Akbostanci MC.
    Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
    [Abstract] [Full Text] [Related]

  • 56. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids.
    Beer KR.
    Dermatol Surg; 2006 Feb; 32(2):184-97. PubMed ID: 16442037
    [Abstract] [Full Text] [Related]

  • 57. Management of the ageing eyebrow and forehead: an objective dose-response study with botulinum toxin.
    Levy JL, Pons F, Jouve E.
    J Eur Acad Dermatol Venereol; 2006 Jul; 20(6):711-6. PubMed ID: 16836501
    [Abstract] [Full Text] [Related]

  • 58. An in vivo analysis of the effect and duration of treatment with botulinum toxin type A using digital image speckle correlation.
    Bhatnagar D, Conkling N, Rafailovich M, Phillips BT, Bui DT, Khan SU, Dagum AB.
    Skin Res Technol; 2013 Aug; 19(3):220-9. PubMed ID: 23565582
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. The Frontalis Activity Measurement Standard: a novel contralateral method for assessing botulinum neurotoxin type-A activity.
    Nestor MS, Ablon GR.
    J Drugs Dermatol; 2011 Sep; 10(9):968-72. PubMed ID: 22052264
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.